Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Cause Mortality Compared to Those with the Lowest Inflammation
News | Cardiovascular Clinical Studies
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023

November 27, 2023 — Esperion announced the presentation of results from a pre-specified, exploratory analysis of CLEAR ...

Home November 27, 2023
Home
First Phase 3 study of TNX-103 in PH-HFpEF patients to start in 4Q 2023 (The LEVEL Study)
News | FDA
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023

November 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home November 27, 2023
Home
News | Atrial Fibrillation
Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

November 24, 2023 — During the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA, Mi ...

Home November 22, 2023
Home
The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.
News | Cardiovascular Clinical Studies
Trial to Prevent Sudden Death After a Heart Attack Enrolls First Patient

November 22, 2023 — The first clinical trial to challenge the routine implantation of a defibrillator in myocardial ...

Home November 22, 2023
Home
News | Pharmaceuticals
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots
News | Heart Valve Technology
Late-breaking Data Show an Aspirin-free Medication Regimen Benefits People with Abbott’s HeartMate 3 Heart Pump

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its He ...

Home November 20, 2023
Home
BioCardia announces that the Food and Drug Administration (FDA) has approved its proposed CardiAMP Heart Failure II study protocol
News | FDA
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

November 17, 2023 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiova ...

Home November 17, 2023
Home
Findings will help scientists understand how microgravity impacts the ability of human heart cells to withstand the stresses of space travel
News | Heart Failure
Mount Sinai Bioengineers Send Cardiac Muscle Samples Into Space to Study Heart Cell Biology in Microgravity

November 16, 2023 — Mount Sinai’s Cardiovascular Research Institute is sending bioengineered human heart muscle cells ...

Home November 16, 2023
Home
In the trial of more than 400 adults with heart failure in Israel, the app predicted the need for hospitalization about three weeks in advance of a heart failure event
News | Heart Failure
AI-phone App Detected Worsening Heart Failure Based on Changes in Patients’ Voices

November 16, 2023 — A smartphone app using artificial intelligence technology to detect changes in the voice of a person ...

Home November 16, 2023
Home
Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our diet is absorbed into our cells
News | Cardiovascular Clinical Studies
Ground-breaking Discovery Could Pave the Way for New Therapies to Prevent Cardiovascular Disease and Stroke

November 15, 2023 — Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our ...

Home November 15, 2023
Home
Ultromics, a leading health technology company at the forefront of detection of heart failure and its phenotypes, announces a significant development regarding the reimbursement code for its flagship product, EchoGo Heart Failure.
News | Heart Failure
CMS publishes final Clinical APC rule for Ultromics EchoGo Heart Failure

November 13, 2023 — Ultromics, a leading health technology company at the forefront of detection of heart failure and ...

Home November 13, 2023
Home
Data from the randomized control trial will advance evidence for evaluation and treatment of heart disease by studying actual disease: atherosclerosis.
News | AHA
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association AHA 2023 Scientific Sessions

November 11, 2023 —  An announcement on partners to collaborate in the TRANSFORM trial was made today during the America ...

Home November 11, 2023
Home
Zerlasiran showed very significant and durable reductions in lipoprotein(a) of up to 99% Lp(a) levels remained around 90% lower than baseline at study endpoint
News | Cardiovascular Clinical Studies
Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

November 10, 2023 — Silence Therapeutics plc, an experienced and innovative biotechnology company committed to ...

Home November 10, 2023
Home
Clinical trial data released during VIVA 2023 Conference included results from a study involving the Veryan Medical BioMimics 3D Vascular Stent System.
News | VIVA
Final Round of Late-breaking Clinical Trial Results Announced at VIVA23

November 9, 2023 — The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular ...

Home November 09, 2023
Home
Artificial intelligence (AI) and deep learning models may help to predict the risk of cardiovascular disease events and detect heart valvular disease, according to two preliminary research studies.
News | Artificial Intelligence
AI May Accurately Detect Heart Valve Disease and Predict Cardiovascular Risk

November 6, 2023 — Advances in artificial intelligence have enabled the development and application of AI tools that may ...

Home November 06, 2023
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now